Student Handout: Chemotherapy Nephrotoxicity
Learning objective: Understand the epidemiology, mechanisms, prevention, and management of traditional chemotherapy and targeted therapy-induced kidney injury
Overview
Chemotherapy-induced nephrotoxicity is one of the most important medication-related complications in oncology. This handout focuses on:
- Platinum agents (cisplatin) — most common & most toxic
- VEGF/TKI agents (tyrosine kinase inhibitors) — increasingly used, different injury pattern
PLATINUM NEPHROTOXICITY (Cisplatin-Focused)
Epidemiology
- Cisplatin: Highly effective chemotherapy for solid tumors (lung, testicular, ovarian, bladder)
- Frequency of AKI: 10–30% at standard doses; up to 60% with high-dose regimens
- Chronic kidney disease: 10–20% of patients develop long-term renal insufficiency
- Risk factors:
- Age >60 years
- Pre-existing CKD or low GFR
- Dehydration
- Concomitant nephrotoxic drugs (NSAIDs, aminoglycosides, amphotericin B)
- Smoking
- Hypomagnesemia
Mechanism of Cisplatin Nephrotoxicity
Step-by-step (simplified):
- Glomerular filtration → Cisplatin freely filtered into tubular lumen
- Uptake → Proximal tubular cells take up cisplatin via organic cation transporters
- Intracellular activation → Cisplatin undergoes aquation, loses chloride, forms reactive platinum species
- DNA binding → Binds DNA in tubular cell nuclei → Formation of DNA adducts
- Cell death → Apoptosis and necrosis of proximal tubular cells
- Clinical result: Acute tubular necrosis (ATN), primarily proximal tubule damage
Clinical Presentation
Acute Kidney Injury (usually 3–7 days post-infusion):
| Finding | Details |
|---|---|
| Timing | Typically 3–7 days after cisplatin dose |
| Labs | ↑ Creatinine (20–30% of baseline is “normal”; >50% is concerning) |
| BUN | Often ↑ proportionally (BUN/Cr ratio ~20) |
| Urinalysis | Muddy casts, epithelial cells, hyaline casts |
| K+ | Often ↓ (hypokalemia from renal wasting) |
| Mg2+ | Often ↓ (renal wasting) |
| Ca2+ | May be ↓ (secondary to Mg2+ loss) |
Chronic Kidney Disease (develops over weeks–months): - Progressive ↓ GFR even after cisplatin discontinuation - Irreversible tubular atrophy and fibrosis in severe cases
Prevention Strategy (CRITICAL)
Aggressive hydration is the #1 prevention tool:
- Before cisplatin:
- 1–2 L IV normal saline over 30–60 min pre-infusion
- Goal: Urine output >150 mL/h during chemotherapy
- During cisplatin infusion:
- Continuous 0.9% or 0.45% NaCl at rates to maintain urine output >100 mL/h
- After cisplatin:
- 1–2 L IV hydration post-infusion (24–48 hours)
- Encourage PO hydration if tolerated
Additional preventive measures:
| Strategy | Details | Evidence |
|---|---|---|
| Amifostine | Mesna analog; free radical scavenger | ↓ AKI risk by 30–40%; use if CrCl >60 |
| Magnesium repletion | Keep Mg >2 mg/dL; supplement if low | Prevents renal Mg wasting |
| Loop diuretics | Furosemide during hydration | Maintains high urine flow |
| Avoid NSAIDs | Hold for ≥48 h pre and post | Reduces GFR; increases cisplatin uptake |
| ACEi/ARB consideration | May offer some protection | Not first-line prevention |
| Antiemetics | Ondansetron, aprepitant | Prevent dehydration from vomiting |
Management of Acute Cisplatin Nephrotoxicity
Grade 1–2 (Cr ↑ <50% or <2× baseline): - Continue hydration (1–2 L daily) - Monitor daily Cr, BUN, K+, Mg - Supplement Mg if low - Consider dose reduction or interval prolongation for next cycle - Most recover within 2–3 weeks
Grade 3–4 (Cr ↑ >50% or >2× baseline, or need RRT): - Aggressive hydration (3–4 L daily) - Renal replacement therapy if oliguria, severe hyperkalemia, or fluid overload - Discontinue or substantially delay cisplatin - Nephrology consult recommended - Expect some permanent renal function loss; recovery incomplete
Long-Term Outcomes
- Recovery timeline: Most recovery occurs within 4–6 weeks; full recovery can take months
- Chronic sequelae: 10–20% of patients develop CKD even after initial recovery
- Monitoring: Annual renal function checks for 5+ years post-treatment
VEGF/TKI NEPHROTOXICITY
Common Agents
| Drug Class | Examples | Cancer Types |
|---|---|---|
| VEGF inhibitors | Bevacizumab (antibody), aflibercept | Colorectal, lung, RCC |
| VEGFR TKIs | Sunitinib, sorafenib, pazopanib | RCC, hepatocellular carcinoma |
| Other TKIs | Axitinib, cabozantinib | RCC, various solid tumors |
Mechanism of VEGF/TKI-Induced Nephrotoxicity
Unlike cisplatin:
- VEGF inhibition → Blocks VEGF signaling in endothelial cells
- Glomerular consequence: Loss of VEGF → Endothelial cell dysfunction, capillary rarefaction, podocyte injury
- Result: Proteinuria (hallmark) + hypertension + mild-moderate AKI
- Histology: If biopsied: FSGS, thrombotic microangiopathy (TMA), or minimal change disease
Epidemiology
- Proteinuria: 5–15% of VEGF/TKI patients develop proteinuria (>0.5 g/day)
- Hypertension: 20–35% develop or worsen hypertension
- Severe AKI: Less common than cisplatin (~2–5%)
- Risk factors:
- Pre-existing HTN or albuminuria
- Diabetes
- Pre-existing CKD
- Concomitant ACEi/ARB use (may protect against proteinuria)
Clinical Presentation
| Feature | Typical Pattern |
|---|---|
| Proteinuria | 0.5–3 g/day; usually non-nephrotic |
| Hematuria | Microscopic; not prominent |
| AKI | Mild-moderate; Cr ↑ 20–50% |
| Hypertension | New onset or worsening in ~30% of patients |
| Reversibility | Often reversible on drug discontinuation (unlike cisplatin) |
Management of VEGF/TKI-Induced Nephrotoxicity
Monitoring: - Baseline: BMP, urinalysis, urine Pt-Cr, BP measurement - During therapy: BMP every 2–4 weeks; urinalysis every 1–2 months
Mild (proteinuria <1 g/day, Cr stable/↑ <20%): - Continue VEGF/TKI therapy - ACEi/ARB at standard doses to reduce proteinuria - Monitor Pt-Cr monthly; repeat q 3 months - BP control — goal <130/80 (2025 AHA/ACC, ADA); KDIGO 2021 suggests systolic <120 on standardized measurement
Moderate (proteinuria 1–3 g/day, Cr ↑ 20–50%): - Continue therapy OR consider dose reduction - Intensify ACEi/ARB (use maximal tolerated doses) - Add amlodipine or hydralazine for BP control - Monitor Pt-Cr q 2 weeks - Nephrology referral if progressive
Severe (proteinuria >3 g/day, Cr ↑ >50%, or nephrotic syndrome): - Consider temporary pause or permanent discontinuation - ACEi/ARB at high doses - Diuretics if edema present - Frequent monitoring (BMP q 1–2 weeks) - Nephrology evaluation mandatory - Some patients recover fully upon discontinuation
Key Difference from Cisplatin
| Feature | Cisplatin | VEGF/TKI |
|---|---|---|
| Injury type | ATN (tubular) | Glomerular (podocyte) |
| Presentation | ↑ Cr, ↓ urine output | Proteinuria, HTN |
| Reversibility | Often permanent loss | Often reversible |
| Prevention | Hydration, amifostine | BP control, ACEi/ARB |
Other Chemotherapy Agents (Brief Reference)
| Agent | Injury | Key Features |
|---|---|---|
| Gemcitabine | Hemolytic uremic syndrome (HUS) | Rare; severe; monitor CBC |
| Ifosfamide | Tubular dysfunction, AKI | Mesna use standard; hydration critical |
| Methotrexate | Crystalline nephropathy | High-dose MTX → aggressive hydration, alkalinization |
| 5-Fluorouracil | Volume depletion, AKI | Supportive care |
| Nitrosoureas | Chronic GFD | Cumulative dose-related |
Integration with Management
Before each cycle: - ✓ Check BMP (especially K, Mg, Cr) - ✓ Baseline BP - ✓ Urine dipstick if on VEGF/TKI - ✓ Ensure adequate hydration status
After cycle: - ✓ Monitor Cr at 3–5 days (cisplatin peak AKI window) - ✓ Replace Mg if <2 mg/dL - ✓ Hydration support
Long-term: - ✓ Annual renal function check post-treatment - ✓ Ongoing HTN management (especially VEGF/TKI patients)
Clinical Pearls
✓ Cisplatin = Hydration is prevention (>1 L pre/post-infusion) ✓ Cisplatin AKI = ATN (muddy casts, high BUN/Cr ratio) ✓ VEGF/TKI = Proteinuria + HTN (glomerular injury pattern) ✓ VEGF/TKI often reversible on drug withdrawal (unlike cisplatin) ✓ Escalate magnesium support for cisplatin patients ✓ Amifostine if CrCl >60 mL/min for high-dose cisplatin
References
- Kidney Cancer Association. Chemotherapy-Induced Acute Kidney Injury. 2021.
- Perazella MA. Chemotherapy Agents and the Kidney. UpToDate. 2024.
- Ronco C, et al. Acute Kidney Injury in High-Risk Populations. Nature Reviews Nephrology. 2020;16:618–625.
- Eremina V, et al. VEGF Inhibition and Renal Thrombotic Microangiopathy. Nature Reviews Nephrology. 2016;12(11):643–653.
Study Tips: - CISPLATIN: Memorize prevention protocol (hydration + amifostine ± loop diuretic) - VEGF/TKI: Remember it causes glomerular proteinuria, not tubular AKI - Use the management tables for quick decision-making in clinical practice - Key insight: Different mechanisms → different prevention and management strategies
Created: 2026-02-28